The recent EU authorisation of lecanemab for the treatment of people with Mild Cognitive Impairment (MCI) in the early stages of Alzheimer’s disease marks a major advance in Alzheimer’s research and treatment. While this authorisation opens new therapeutic possibilities, its implementation in clinical practice presents several challenges. Identifying eligible individuals, those with amyloid beta plaques in the brain and carrying one or no copies of the ApoE4 gene, requires improved diagnostic pathways, use of validated biomarkers and access to specialist services. The introduction of disease-modifying therapies like lecanemab also raises questions around clinical capacity, cost-effectiveness and equitable access.
The PROMINENT project is responding to these challenges. It is developing a digital platform to support clinicians with AI-powered decision tools that integrate genetic, imaging and clinical data. This platform will provide personalised diagnostic and prognostic support, and offer patients and care partners tailored information on brain health. Validation and implementation studies involving clinicians, patients and care partners are underway. These will assess the platform’s clinical accuracy, ease of use and impact on care.
PROMINENT also aims to support real-world adoption through collaboration with HTA bodies, regulators and payers. PROMINENT is coordinated by Karolinska Institutet and brings together clinical, academic and industry partners, in-cluding BioArctic and Combinostics, as well as Alzheimer Europe, representing 41 national Alzheimer’s associations across 36 countries.
Find out more about our work: https://www.ihi-prominent.eu/work-plan/
Read the European Commission’s announcement on the authorisation of lecanemab: https://ec.europa.eu/newsroom/sante/items/879055/en